Journal Article Epublish
PubMed: 42931423 DOI: 10.3390/vaccines14100894
Factors Associated with Intention to Receive the TAK-003 Dengue Vaccine Among Adults in Endemic Regions of Peru: A Cross-Sectional Study.
Vaccines (Basel) 14(10)
Authors: Jose Armando Gonzales-Zamora, Julieta Maribel Araoz-Salinas, Carlos Quispe-Vicuña, Gabriel Aquino-Sandoval, Martin Ernesto Reategui-Garcia, Allison Nicole Ortiz-Pardo, Abraham De-Los-Rios-Pinto, Noelia Morocho-Alburqueque, Silvia Celeste Tipe-Gonzales, Wagner Rios-Garcia, Anderson Nelver Soriano-Moreno, Brando Ortiz-Saavedra, José Miguel Rios-Osorio, Ruth Ramon-Tapia, Jorge Alave
Affiliations
- Peruvian American Medical Society, Ann Arbor, MI 48104-1059, USA.
- Grupo de Investigación Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria (NEMECS) y Centro Cochrane, Universidad Científica del Sur, Lima 15067, Peru.
- Facultad de Medicina Humana, Universidad Nacional de la Amazonía Peruana, Iquitos 16000, Peru.
- Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco 08003, Peru.
- Facultad de Ciencias de la Salud, Universidad Nacional de Piura, Castilla, Piura 20002, Peru.
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.
- Facultad de Medicina, Universidad Nacional San Luis Gonzaga, Ica 11001, Peru.
- Unidad de Investigación Clínica y Epidemiológica, Escuela de Medicina, Universidad Peruana Unión, Lima 15464, Peru.
- Cardiovascular Surgery Department, Instituto Nacional Cardiovascular Carlos Alberto Peschiera Carrillo, EsSalud, Lima 15072, Peru.
- Facultad de Medicina "Hipólito Unanue", Universidad Nacional Federico Villarreal, Lima 15088, Peru.
- NYC Health + Hospitals/Lincoln, Bronx, NY 10451, USA.
Abstract
BACKGROUND
Dengue vaccination is a promising preventive strategy. Peru introduced the TAK-003 vaccine in November 2024 for children aged 10-16 years and expanded it in January 2026 to individuals aged 10-20 years and selected priority adult groups. This study evaluated perceptions and intention to receive the dengue vaccine among adults before this expansion.
METHODS
We conducted an analytical cross-sectional study among adults living in Peruvian regions with medium or high dengue incidence. Participants completed a web-based questionnaire between 22 March and 13 April 2025 that assessed their perceptions of dengue vaccination and intention to receive the vaccine. To determine the associated factors, we estimated crude Prevalence Ratios (cPR) and adjusted Prevalence Ratios (aPR) with 95% Confidence Intervals (95% CI) using crude and multivariable Poisson regression models with robust variance.
RESULTS
We included 459 participants with a median age of 28 years; of them, 61.2% were women, and 73.6% lived in the coastal region. Overall, 91.5% intended to receive the dengue vaccine. Most considered the vaccine necessary (80.2%) and believed that it protected against severe dengue (67.1%). However, only 24.2% considered the information provided by the Peruvian Ministry of Health adequate. In the crude analysis, vaccination intention was associated with previous receipt of dengue vaccine information and several perceptions regarding vaccine necessity, effectiveness, adverse effects, and healthcare professional recommendations. After multivariable adjustment, only prior receipt of dengue vaccine information remained independently associated with greater vaccination intention (aPR: 1.05; 95% CI: 1.00-1.10; p = 0.039).
CONCLUSIONS
Most participants intended to receive the dengue vaccine and generally reported favorable perceptions toward vaccination. Previous receipt of dengue vaccine information was independently associated with greater vaccination intention. Therefore, clear and evidence-based educational strategies may support informed vaccination decisions. Further research is needed to validate these findings and explore other factors associated with dengue vaccination.
MeSH
Cross-Sectional Studies, Vaccines, Perception, Vaccination, Aged, Dengue, Dengue Vaccines